Overview

Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS

Status:
Active, not recruiting
Trial end date:
2025-05-07
Target enrollment:
Participant gender:
Summary
The OLE study aims to investigate the safety, efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and immunogenicity of efgartigimod in participants with post-COVID-19 postural orthostatic.
Phase:
Phase 2
Details
Lead Sponsor:
argenx
Collaborator:
Iqvia Pty Ltd